Not the Usual Suspects: FDA Seeks New Advisors for Risk Communication Committee
This article was originally published in RPM Report
The Food & Drug Administration is bringing a whole new constituency into the advisory committee process with the creation of an expert panel focused on improving the way the agency communicates risk information to the public. For industry, success will require even greater attention to foresee and address safety issues.
You may also be interested in...
A year ago, Congress sent FDA two very clear, somewhat contradictory messages: Hold more advisory committee meetings, but without the use of many expert panelists used in the past. The result is a system that is stretched to the limits.
There is no question someone is over-reacting to safety issues with Biogen Idec/Elan's Tysabri and Lilly/Amylin's Byetta. But is it FDA-or investors?
Members of FDA Risk Communications Advisory Committee. Wyeth R&D senior execs meet with FDA drug review managers in September 2007. Oncologists, an ex-Congresswoman, and a former Bush Administration health policy advisor met with FDA senior managers (including Commissioner von Eschenbach) in October before FDA decidied to support the Centers for Medicare and Medicaid Services in its effort to restrict use of EPO for chemotherapy patients.